Close

Array BioPharma (ARRY) Could Trade up 50-75% Amid Positive COLUMBUS Trial Results - JPMorgan

September 26, 2016 9:43 AM EDT Send to a Friend
JPMorgan analyst Anupam Rama weighed in on Array BioPharma (NASDAQ: ARRY) after the company and partner Pierre Fabre announced positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login